Michael E. Castagna is the CEO of MannKind Corporation, a pharmaceutical company known for its innovative diabetes treatments. He became CEO in May 2017 after previously serving as the Chief Commercial Officer. With a PharmD from Albany College of Pharmacy...

Michael E. Castagna is the CEO of MannKind Corporation, a pharmaceutical company known for its innovative diabetes treatments. He became CEO in May 2017 after previously serving as the Chief Commercial Officer. With a PharmD from Albany College of Pharmacy and significant experience in the industry, he has worked with big names like Amgen and Bristol-Myers Squibb. Castagna stepped into leadership at MannKind during a pivotal time when the company was launching its flagship product, Afrezza.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Mannkind CEOs

M

Michael E. Castagna

CEO of Mannkind

Education

PharmD from Albany College of Pharmacy

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

January 1, 1976 - 49 years ago

CEO of Mannkind for

8 years 2 months (May 2017 - Present)

Previous Experience

Chief Commercial Officer at MannKind Corporation

Rivals

Competitors/colleagues of Michael E. Castagna

Holdings

See how much did Michael E. Castagna make over time.

Michael Castagna has seen significant changes in his stock holdings since becoming CEO. His stake in MannKind reflects the company's rollercoaster stock performance. Notably, his holdings reached a high of around $14 million in value as of September 2024, showcasing...

Michael Castagna has seen significant changes in his stock holdings since becoming CEO. His stake in MannKind reflects the company's rollercoaster stock performance. Notably, his holdings reached a high of around $14 million in value as of September 2024, showcasing his deep connection to the company's fate. In contrast, his earlier trades in 2020 showed a range from $185K to $346.62K as market conditions fluctuated. These differences highlight how his financial well-being is tied to the company's success.

Loading...

Total Stock Sold

$3.19M

MNKD

$3.19M

695,588 MNKD shares

What if they kept their stock?

If Michael E. Castagna didn't sell their stock, today they would have:
Extra MNKD695,588 shares worth $1.15M.
This is -63.99% and $2.04M less than what they got when they sold the stock.

Charitable Transactions

MNKD

32,894 shares

MNKD

Recent Charitable Transactions

MNKD

32,894 shares

MNKD

Aug 27, 2024

Charity

Insider Trading

See recent insider trades of Michael E. Castagna.

MNKD

32,894 shares

MNKD

Aug 27, 2024

Charity

MNKD

$536.17K

MNKD at $6.30/share

Aug 27, 2024

Sale

MNKD

$15.45K

MNKD at $3.09/share

Jul 15, 2024

Received

MNKD

$1.02M

MNKD at $4.59/share

May 17, 2024

Received

MNKD

465,000 shares

MNKD

May 15, 2024

Received

MNKD

$115.96K

MNKD at $3.27/share

Jun 30, 2023

Received

MNKD

$801.93K

MNKD at $4.00/share

Dec 14, 2023

Sale

MNKD

$42.50K

MNKD at $4.25/share

Nov 1, 2023

Sale

MNKD

$46.10K

MNKD at $4.61/share

Oct 2, 2023

Sale

MNKD

$40.80K

MNKD at $4.08/share

Oct 2, 2023

Sale

Compensation History

See how much did Michael E. Castagna make over time.

In 2023, Michael Castagna's total compensation was about $7 million, which included a base salary and bonuses tied to the company's performance. His bonus structure is ambitious, reflecting how well the company met its corporate goals. This pay structure aligns his interests with those of MannKind's investors, ensuring he has a strong incentive to increase shareholder value over time. In previous years, his compensation varied significantly, which illustrates how his earnings evolve with the company's performance indicators.

Year

2023

Total Compensation

$9.59M

Salary

$701.55K

Board Justification

The compensation philosophy is to provide a competitive compensation package that aligns with the company's performance and market benchmarks, focusing on attracting and retaining qualified executives while promoting long-term stockholder value.

Bonus

$808.18K

Board Justification

The annual cash incentive awards under the STI plan are based on individual performance in the achievement of corporate objectives. Performance is compared to these objectives annually, with the company achieving 144% of its corporate goals for 2023.

Other

$21.84K

Board Justification

Includes employer contributions to the 401(k) plan and medical benefits.

Restricted Stock

$8.06M(1.71M RSU)

Board Justification

The stock awards that vested in 2023 were primarily from restricted stock units, which are tied to the company's performance and vesting schedules.

Performance Metrics

The performance metrics for 2023 included total revenue, total shareholder return, and specific operational goals related to production and business development.

Other Mannkind CEOs

Here are other CEOs of Mannkind

Matthew J. Pfeffer

Ex-CEO of Mannkind

January 2016 - May 2017